Q1 Earnings Estimate for Amgen Issued By Leerink Partnrs

Amgen Inc. (NASDAQ:AMGN) – Analysts at Leerink Partnrs issued their Q1 2025 earnings estimates for shares of Amgen in a research report issued on Wednesday, February 5th. Leerink Partnrs analyst D. Risinger anticipates that the medical research company will post earnings per share of $4.45 for the quarter. The consensus estimate for Amgen’s current full-year earnings is $19.56 per share. Leerink Partnrs also issued estimates for Amgen’s Q2 2025 earnings at $5.67 EPS, Q3 2025 earnings at $5.47 EPS, Q4 2025 earnings at $5.12 EPS, FY2025 earnings at $20.71 EPS and FY2027 earnings at $20.75 EPS.

Several other research analysts have also commented on AMGN. Wells Fargo & Company reduced their price target on Amgen from $335.00 to $280.00 and set an “equal weight” rating on the stock in a report on Friday, January 10th. Leerink Partners reduced their price target on Amgen from $349.00 to $302.00 in a report on Wednesday, November 27th. Truist Financial reduced their price target on Amgen from $333.00 to $298.00 and set a “hold” rating on the stock in a report on Wednesday, January 8th. Redburn Partners reduced their price objective on shares of Amgen from $200.00 to $195.00 in a report on Wednesday, November 27th. Finally, Royal Bank of Canada restated an “outperform” rating and issued a $324.00 price objective on shares of Amgen in a report on Friday, January 24th. Two research analysts have rated the stock with a sell rating, twelve have issued a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, Amgen presently has a consensus rating of “Hold” and a consensus price target of $314.83.

Amgen Trading Down 3.3 %

Shares of AMGN opened at $297.78 on Thursday. Amgen has a 52-week low of $253.30 and a 52-week high of $346.85. The company has a quick ratio of 0.96, a current ratio of 1.32 and a debt-to-equity ratio of 7.55. The firm’s fifty day moving average is $271.69 and its two-hundred day moving average is $303.55. The stock has a market cap of $160.07 billion, a PE ratio of 38.13, a price-to-earnings-growth ratio of 2.87 and a beta of 0.56.

Amgen (NASDAQ:AMGN) last announced its earnings results on Tuesday, February 4th. The medical research company reported $5.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.04 by $0.27. Amgen had a net margin of 13.00% and a return on equity of 168.35%.

Institutional Investors Weigh In On Amgen

A number of institutional investors and hedge funds have recently added to or reduced their stakes in AMGN. Pathway Financial Advisers LLC lifted its stake in Amgen by 33,125.4% in the third quarter. Pathway Financial Advisers LLC now owns 4,460,181 shares of the medical research company’s stock valued at $1,437,115,000 after buying an additional 4,446,757 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its stake in Amgen by 25.4% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 13,205,604 shares of the medical research company’s stock valued at $3,441,909,000 after buying an additional 2,672,975 shares during the last quarter. International Assets Investment Management LLC lifted its stake in Amgen by 6,812.4% in the third quarter. International Assets Investment Management LLC now owns 2,523,387 shares of the medical research company’s stock valued at $8,130,610,000 after buying an additional 2,486,882 shares during the last quarter. Raymond James Financial Inc. purchased a new stake in shares of Amgen during the fourth quarter worth approximately $401,913,000. Finally, Assenagon Asset Management S.A. raised its stake in shares of Amgen by 561.5% during the third quarter. Assenagon Asset Management S.A. now owns 1,539,733 shares of the medical research company’s stock worth $496,117,000 after purchasing an additional 1,306,982 shares during the last quarter. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Insider Activity at Amgen

In related news, SVP Nancy A. Grygiel sold 1,589 shares of the company’s stock in a transaction that occurred on Wednesday, February 5th. The stock was sold at an average price of $304.47, for a total value of $483,802.83. Following the completion of the transaction, the senior vice president now directly owns 7,210 shares of the company’s stock, valued at $2,195,228.70. This represents a 18.06 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.69% of the stock is currently owned by corporate insiders.

Amgen Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, February 14th will be given a dividend of $2.38 per share. The ex-dividend date is Friday, February 14th. This is an increase from Amgen’s previous quarterly dividend of $2.25. This represents a $9.52 dividend on an annualized basis and a dividend yield of 3.20%. Amgen’s payout ratio is currently 126.09%.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.